PHT Adopts Vodafone M2M Tech
Vodafone’s Machine-to-Machine (M2M) technology enables PHT Corporation to more efficiently manage worldwide clinical trials through real-time access to patient experience data
Vodafone and PHT Corporation, a provider of technologies used to collect electronic data for clinical research from patients, will connect the PHT electronic clinical outcome assessment (eCOA) system to Vodafone’s global M2M network. Using Vodafone’s global M2M network, PHT can provide pharmaceutical trial sponsors real-time access to patient data. Currently the PHT eCOA System is used to collect data in clinical trials in more than 75 countries.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
